News

New generation antibiotics to treat drug resistant infections

Synamp Pharmaceuticals announced as winner of the Health~Holland Venture Challenge Fall Edition.
New generation antibiotics to treat drug resistant infections

Health~Holland Update, November 2015

We are pleased to publish the fifth edition of the bimonthly Health~Holland Update, our magazine that brings you the latest insights and developments from Health~Holland (Top Sector Life Sciences & Health).
Health~Holland Update, November 2015

Hubrecht Institute partners up with Top Sector LSH

The Hubrecht Institute enter a public-private partnership with the Top Sector Life Sciences & Health.
Hubrecht Institute partners up with Top Sector LSH

Schippers introduces Health Deals

Minister Edith Schippers (VWS) heeft vandaag mede namens haar collega Henk Kamp (EZ) de aftrap gegeven voor het aangaan van ‘Health Deals’. Zij deed dit door een digitaal loket voor informatie over - en ondersteuning bij - het opstarten van deze zorgprojecten te openen.
Schippers introduces Health Deals

Hechten met één hand, mede dankzij Innovatiekrediet

Zorg voor een goede analyse van de markt en van de klantwaarde. Deze les leerde Mellon Medical. Het bedrijf ontwikkelt de Switch, een precisie-hechtinstrument voor chirurgen.
Hechten met één hand, mede dankzij Innovatiekrediet

Pharma Boardroom Interview Hans Schikan

Hans Schikan offers insights into the flourishing Dutch life sciences sector and the attractiveness of the local eco-system, citing a combination of the right science and the right attitude of people as the key formula for success.
Pharma Boardroom Interview Hans Schikan

Hercules Receives €3.5 Million EUROSTARS Grant for Further Development of a New Drug for Triple Negative Breast Cancer

Hercules Pharmaceuticals BV, a biopharmaceutical company developing an innovative treatment for women with Triple Negative Breast Cancer (TNBC), has been awarded a € 3,5 million Eurostars grant for the development of its lead drug CB7993113 for treatment of TNBC.
Hercules Receives €3.5 Million EUROSTARS Grant for Further Development of a New Drug for Triple Negative Breast Cancer

InteRNA Technologies Secures Final Extension Series A Financing and Strengthens Its Supervisory Board

InteRNA Technologies B.V., a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, announces the closing of an equity financing round. This final extension of its Series A was co-led by new investors INKEF Capital and Aglaia Oncology Fund II. Existing shareholders also participated in this round, bringing the total Series A funding to US$ 10.5 million.
InteRNA Technologies Secures Final Extension Series A Financing and Strengthens Its Supervisory Board

New Partnership with India Aims to Build Vaccine Manufacturing Network for Hookworm, Other Diseases

The Amsterdam Institute for Global Health and Development (AIGHD) and Sabin Vaccine Institute Product Development Partnership (Sabin PDP) announced a new research and innovation partnership with the Association of Biotechnology Led Enterprises (ABLE) of India on vaccine development for hookworm and other neglected tropical diseases (NTDs).
New Partnership with India Aims to Build Vaccine Manufacturing Network for Hookworm, Other Diseases

Inventory Dutch Antibiotic Research

Het ministerie van VWS heeft InnoTact Consulting verzocht om een nationale samenwerkingsstructuur uit te werken. Als onderdeel hiervan inventariseren we de Nederlandse onderzoeks- en ontwikkelingsprojecten en programma’s die leiden tot nieuwe antibiotica, alternatieve behandelingen (peptiden, bacteriofagen, vaccins etc) of hiervoor in te zetten technologieën.
Inventory Dutch Antibiotic Research